23:13 , Jun 14, 2019 |  BC Extra  |  Company News

bluebird prices β thalassemia gene therapy, first to put majority of revenues at risk

bluebird bio could be the first company to test an outcomes-based pricing model for a gene therapy where the vast majority of the price is at risk. On Friday, bluebird bio Inc. (NASDAQ:BLUE) announced the...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
00:43 , Jun 14, 2019 |  BC Extra  |  Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
21:41 , Jun 13, 2019 |  BC Innovations  |  Emerging Company Profile

Gracell: Speeding up CAR T cells

With a platform that could reduce the manufacturing time of autologous CAR T cells from two weeks to one day, Gracell is lining up a set of therapies it could produce with the method. Gracell...
20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
22:01 , Jun 10, 2019 |  BC Extra  |  Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...
00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
10:52 , Jun 7, 2019 |  BC Extra  |  Company News

As Sanofi enters growth phase, Novartis exec Hudson to take the helm

Novartis has lost one executive from each of its Innovative Medicines units in the span of three days, now that Sanofi has named seasoned British sales and marketing executive Paul Hudson as the successor to...